Figure 1From: Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis Progression-free survival of mCRC patients treated with bevacizumab in combination with FOLFOX or XELOX. Back to article page